WallStreetZenWallStreetZen

NASDAQ: HRTX
Heron Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell HRTX stock?

Based on 2 analysts offering ratings for Heron Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HRTX stock forecasts and price targets.

HRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-06-03

1 of 1

Forecast return on equity

Is HRTX forecast to generate an efficient return?

Company
616.72%
Industry
21.25%
Market
168.71%
HRTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HRTX forecast to generate an efficient return on assets?

Company
16.89%
Industry
23.75%
HRTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HRTX earnings per share forecast

What is HRTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.13
Avg 2 year Forecast
-$0.11
Avg 3 year Forecast
-$0.06

HRTX revenue forecast

What is HRTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$151.2M+0.03%
Avg 2 year Forecast
$148.8M-1.56%
Avg 3 year Forecast
$163.8M+8.32%
HRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HRTX revenue growth forecast

How is HRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
2.7%
Industry
32.77%
Market
13.78%
HRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HRTX$0.31N/AN/AHold
NMAD$3.61N/AN/A
EXOZ$6.44N/AN/A
XLO$9.13N/AN/A
DWTX$1.69$12.00+610.06%Buy
View Top Biotech Stocks

Heron Therapeutics Stock Forecast FAQ

Is Heron Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: HRTX) stock is to Hold HRTX stock.

Out of 2 analysts, 0 (0%) are recommending HRTX as a Strong Buy, 0 (0%) are recommending HRTX as a Buy, 2 (100%) are recommending HRTX as a Hold, 0 (0%) are recommending HRTX as a Sell, and 0 (0%) are recommending HRTX as a Strong Sell.

If you're new to stock investing, here's how to buy Heron Therapeutics stock.

What is HRTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: HRTX) Heron Therapeutics's current Earnings Per Share (EPS) is -$0.18. On average, analysts forecast that HRTX's EPS will be -$0.13 for 2026, with the lowest EPS forecast at -$0.14, and the highest EPS forecast at -$0.13. On average, analysts forecast that HRTX's EPS will be -$0.11 for 2027, with the lowest EPS forecast at -$0.12, and the highest EPS forecast at -$0.11. In 2028, HRTX's EPS is forecast to hit -$0.06 (min: -$0.06, max: -$0.05).

What is HRTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: HRTX) forecast ROE is 616.72%, which is considered strong.

What is HRTX's earnings growth forecast for 2026-2028?

(NASDAQ: HRTX) Heron Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Heron Therapeutics's earnings in 2026 is -$34,049,000.On average, 4 Wall Street analysts forecast HRTX's earnings for 2026 to be -$25,554,121, with the lowest HRTX earnings forecast at -$26,047,737, and the highest HRTX earnings forecast at -$24,718,770. On average, 4 Wall Street analysts forecast HRTX's earnings for 2027 to be -$21,681,133, with the lowest HRTX earnings forecast at -$22,326,631, and the highest HRTX earnings forecast at -$20,731,872.

In 2028, HRTX is forecast to generate -$10,745,641 in earnings, with the lowest earnings forecast at -$11,163,316 and the highest earnings forecast at -$10,176,084.

What is HRTX's revenue growth forecast for 2026-2028?

(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 2.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Heron Therapeutics's revenue in 2026 is $151,178,000.On average, 4 Wall Street analysts forecast HRTX's revenue for 2026 to be $28,709,465,865, with the lowest HRTX revenue forecast at $27,481,121,438, and the highest HRTX revenue forecast at $29,662,524,446. On average, 4 Wall Street analysts forecast HRTX's revenue for 2027 to be $28,253,820,328, with the lowest HRTX revenue forecast at $27,126,097,624, and the highest HRTX revenue forecast at $29,104,358,663.

In 2028, HRTX is forecast to generate $31,090,213,794 in revenue, with the lowest revenue forecast at $29,637,843,646 and the highest revenue forecast at $32,254,008,436.

What is HRTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: HRTX) forecast ROA is 16.89%, which is lower than the forecast US Biotechnology industry average of 23.75%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.